News

- CRISPR Therapeutics and Vertex announce authorization of the first CRISPR/Cas9 Gene- Edited Therapy, CASGEVY™, by the UK MHRA
- Arcellx and Kite announce expansion in strategic partnership
- US FDA approves Bristol- Myers Squibb's (BMY.N) lung cancer drug that was acquired as part of the company's $4.1B buyout of Turning Point Therapeutics (TPTX)
- Dren Bio appoints Amit Mehta as Chief Operating Officer and Chief Business Officer
- Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
- Rezo Therapeutics appoints Nadir Mahmood as CEO
- Nimbus Therapeutics secures $210M in private financing
- FORE Biotherapeutics announces $75M in Series D and CEO Transition
- ADARx Pharmaceuticals announces oversubscribed $200M Series C
- Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)
- Nkarta appoints Alyssa Levin CBO and CFO
- FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia
- HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B
- Simcha Therapeutics announces clinical trial collaboration with Merck to evaluate ST-067 in combination with KEYTRUDA® (Pembrolizumab)
- SR One Closes Second Venture Fund at $600M
- Mineralys Therapeutics prices $221M IPO
- ADARx Pharmaceuticals raises $46M in Series B-1 and appoints Dr. Lorence Kim to Board of Directors
- ADARx Pharmaceuticals appoints Robert MacLeod as CSO
- Akamis Bio raises $30M financing and relaunches with name change from PsiOxus Therapeutics
- HotSpot Therapeutics announces FDA clearance of IND application for HST-1011, an investigational small molecule allosteric inhibitor of CBL-B
- Nimbus Therapeutics TYK2 program to be acquired by Takeda for $4B in upfront cash and up to $2B in potential commercial milestone payments
- Arcellx announces strategic collaboration with Kite, a Gilead Company, to co-develop and co- commercialize late- stage clinical CART-ddBCMA in multiple myeloma
- HotSpot Therapeutics launches strategic collaboration with AbbVie to further expand immunology pipeline
- Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor
- Rezo Therapeutics, founded by renowned UCSF scientists, raises $78M in Series A
- ARS Pharmaceuticals closes merger with Silverback Therapeutics and currently has over $280M in cash
- Nimbus Therapeutics appoints Nathalie Franchimont as CMO
- Odyssey Therapeutics raises $168M in Series B
- Nimbus Therapeutics announces research collaboration and license agreement with Lilly
- ADARx Pharmaceuticals appoints Christopher Prentiss as CFO
- Nimbus Therapeutics closes $125M in private financing
- Simcha Therapeutics accelerates growth with key leadership appointments, expanded research and option agreement with Yale School of Medicine
- PsiOxus Therapetuics appoints Howard Davis as CEO
- MiroBio to be acquired by Gilead Sciences for $405M
- HotSpot Therapeutics appoints Paul Thibodeau as CBO
- ARS Pharmaceuticals and Silverback Therapeutics announces merger
- HotSpot Therapeutics appoints Jose Carmona to Board of Directors
- Ancora Biotech lead clinical asset, TeneoTwo, to be acquired by AstraZeneca for up to $1.27B
- MiroBio raises $97M in Series B
- Arcellx raises $128M in follow-on financing
- Arcellx appoints Maryam Abdul-Kareem as General Counsel
- Dren Bio raises $65M in Series B
- CRISPR Therapeutics and Vertex presents new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel)
- CRISPR Therapeutics presents positive results from its Ph1 COBALT™-LYM trial of CTX130™ in relapsed or refractory T cell malignancies
- Ancora Biotech raises $60M in Series A
- Mineralys Therapeutics raises $118M in Series B
- eFFECTOR Therapeutics reports positive interim results in zotatifin (EFT226) Ph1/2 clinical trial
- Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial
- Turning Point Therapeutics to be acquired by Bristol Myers Squibb for $4.1B
- Odyssey Therapeutics appoints Darryl Patrick as Executive Vice President of Non-Clinical Development
- Arcellx appoints Michelle Gilson as CFO
- Odyssey Therapeutics appoints Jeffrey M. Leiden as Board Chair
- Arcellx appoints Olivia Ware to Board of Directors
- CRISPR Therapeutics appoints Phuong Khanh Morrow as CMO
- Arcellx announces dosing of first patient in its Ph1 clinical trial evaluating ACLX- 001, the first therapeutic in the dosable and controllable ARC- SparX Platform
- Nkarta Therapeutics raises $230M in follow-on financing
- Nkarta Therapeutics announces positive preliminary dose finding data for two lead engineered natural killer cell programs
- BioTheryX appoints Jeff Caravella as CFO
- CRISPR Therapeutics appoints Maria Fardis to Board of Directors
- ARS Pharmaceuticals appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as CFO
- Nimbus Therapeutics presents clinical data from Ph1 study of oral allosteric TYK2 inhibitor at AAD Annual Meeting
- MiroBio continues expansion of executive leadership team
- BioTheryX appoints Nancy Miller- Rich as Board Chair
- eFFECTOR Therapeutics appoints Kristen Harrington-Smith to Board of Directors
- Second Genome nominates development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease
- Decibel Therapeutics reports on continued progress of lead gene therapy product candidate DB-OTO
- ARS Pharmaceuticals expands executive leadership team
- Arcellx prices $142.3M IPO
- Nimbus Therapeutics shares update on discovery efforts in computational chemistry and expands leadership team
- CRISPR Therapeutics and ViaCyte announce first patient dosed in Ph1 clinical trial
- Design Therapeutics appoints Jae Kim as CMO
- Simcha Therapeutics raises $40M in Series B
- BioTheryX doses first patient in Ph1 study investigating lead protein degrader candidate BTX-1188
- ADARx Pharmaceuticals expands leadership team
- Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer
- Palleon Pharmaceuticals announces IND clearance for its lead candidate E-602
- BioTheryX appoints Sahm Nasseri as CBO
- Second Genome appoints Joseph Dal Porto as CSO
- Dren Bio announces research collaboration and license agreement with Pfizer
- HotSpot Therapeutics and Caris Life Sciences announce collaboration
- Nimbus Therapeutics announces expansion of oral allosteric TYK2 inhibitor program
- Odyssey Therapeutics acquires Rahko
- ADARx Pharmaceuticals appoints Dr. Hubert Chen as CMO
- Bicycle Therapeutics announces continued clinical progress and updates to management team
- Second Genome granted U.S. patent for proteins for the treatment or prevention of epithelial barrier function disorders
- Palleon Pharmaceuticals appoints Denis Patrick to its Board of Directors
- Nkarta receives U.S. FDA orphan drug designation for NKX101 for treatment of patients with AML
- Arcellx presents continued robust long-term responses from its CART-ddBCMA Ph1 expansion trial
- Tranquis Therapeutics announces initiation of Ph1 study of TQS-168
- Nomic Bio raises $17M in Series A
- Odyssey Therapeutics raises $218M in Series A
- Pulmocide receives $3.5M investment from the Cystic Fibrosis Foundation
- HotSpot Therapeutics raises $100M in Series C
- CRISPR Therapeutics announces FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted to CTX110™
- Palleon presents data on sialoglycan degradation platform that enhances anti-tumor T-cell immunity
- Tranquis Therapeutics presents positive preclinical data on TQS-168 for the treatment of ALS
- BioTheryX receives IND clearance from FDA to proceed with Ph1 Study of BTX-1188
- Palleon Pharmaceuticals appoints David Johnson to its Board of Directors
- BioTheryX appoints Philippe Drouet as CEO
- Bicycle Therapeutics raises $201.3M
- CRISPR Therapeutics reports positive results from its Ph1 CARBON Trial of CTX110™
- Bicycle Therapeutics announces preliminary results from Ph1 oncology trials
- Turning Point Therapeutics granted breakthrough therapy designation for Repotrectinib treatment
- MiroBio appoints Dr. Carolin Barth as CEO
- PsiOxus Therapeutics to present positive biomarker data at ESMO 2021
- ADARx Pharmaceuticals raises $75M in Series B
- ARS Pharmaceuticals raises $55M in Series D
- eFFECTOR Therapeutics debuts as public company
- Turning Point Therapeutics initiates Ph1b/2 combination study
- BioTheryX appoints three new members to its Board of Directors
- eFFECTOR Therapeutics initiates Zotatifin Ph2a in breast and lung cancers
- eFFECTOR Therapeutics doses first COVID- 19 patient in Zotatifin Ph1b trial
- Bicycle Therapeutics enters exclusive license and collaboration agreement with Ionis
- Nimbus Therapeutics raises $105M from top investors
- Morphic Therapeutic new data from positive Ph1 study of MORF-057
- Turning Point Therapeutics receives orphan drug designation for TPX-0022 in gastric cancer
- CRISPR Therapeutics and Capsida Biotherapeutics announce strategic collaboration
- eFFECTOR Therapeutics doses first patient in Ph2b kickstart clinical trial
- eFFECTOR Therapeutics and Locust Walk Acquisition Corp Annouce Merger
- Pulmocide raises $92M in Series C
- Tranquis Therapeutics appoints Frederic Godderis as COO and Jonas Hannestad as CMO
- Turning Point Therapeutics appoints Mark Alles to chair its Board of Directors
- BioTheryX raises $92M in Series E
- Fore Biotherapeutics strengthens leadership team
- Arcellx to present data at ASCO 2021
- CRISPR Therapeutics and Nkarta announce global collaboration
- eFFECTOR Therapeutics and UCSF receive $5M from DARPA for Covid study
- CRISPR Therapeutics amends partnership with Vertex Pharmaceuticals
- Arcellx appoints Dr. Christopher as CMO and Neeraj Teotia as CCO
- HotSpot Therapeutics appoints Timothy Reilly as Chief Development Officer
- PsiOxus Therapeutics and bluebird bio present preclinical data at AACR 2021
- Arcellx raises $115M in Series C
- Bicycle Therapeutics presents preclinical data at AACR 2021
- Pandion Therapeutics acquired by Merck for $1.85BN
- Design Therapeutics prices $276M IPO
- Bicycle Therapeutics appoints Jose-Carlos Gutierrez-Ramos as Board Director
- Positive clinical updates of PC945 in lung infections
- Positive interim Phase 1 results of oral integrin therapy
- Preclinical data supporting local immune modulation platform
- Fore Biotherapeutics appoints Dieter Weinand as Board Chairman and Usama Malik as CEO and Board Director
- Decibel Therapeutics prices $127M IPO
- SR One adds Venture Partners to deepen operational expertise
- Design Therapeutics raises $125M Series B
- Narrow River management raises $40M each for two new renal companies
- Arcellx appoints Rami Elghandour as Chairman and CEO
- Second Genome appoints Dr. Susannah Cantrell as CBO and Dr. Preeti Gupta Lal as CSO
- Clinical progress across oncology pipeline
- eFFECTOR Therapeutics appoints Mike Byrnes as CFO
- FDA accepts BLA for Reltecimod
- Repotrectinib treatment in TKI naive patients granted FDA breakthrough therapy designation
- Cell therapy demonstrates durable responses in multiple myeloma
- Update on gene editing for sickle cell disease and beta-thalassemia
- Morphic Therapeutic appoints Dr. Martin W. Edwards as Board Director
- Palleon Pharmaceuticals appoints Deepa Pakianathan as Board Director
- Pandion Therapeutics appoints Katina Dorton as Board Director
- SR One Raises $500M; Completes Spinout from GSK
- HotSpot Therapeutics appoints Eva Jack as COO
- Decibel Therapeutics raises $82M Series D
- Mission Therapeutics appoints Dr. Suhail Nurbhai as CMO
- Turning Point Therapeutics raises $400M
- Early response data with gene edited cell therapy for B-cell malignancies
- Design Therapeutics appoints Joao Siffert as CEO
- Nobel Prize in chemistry awarded to CRISPR Therapeutics founder Emmanuelle Charpentier
- Dren Bio raises $60M Series A
- eFFECTOR Therapeutics appoints Premal Patel as CMO
- Nimbus Therapeutics raises $60M
- Nkarta Therapeutics appoints Nadir Mahmood as CFO/CBO and Alicia J. Hager as Chief Legal Officer
- Fore Biotherapeutics raises $57M Series C
- Palleon Pharmaceuticals raises $100M Series B
- Early interim data from Trident-1, a registrational Phase 2 of Repotrectinib
- Principia Biopharma acquired by Sanofi for $3.7BN
- Pandion Therapeutics prices $135M IPO
- Nkarta Therapeutics prices $290M IPO
- Tranquis Therapeutics raises $30M Series A
- Mission Therapeutics raises $15M
- CRISPR Therapeutics raises $450M
- Tomivosertib demonstrates positive Phase 2 results in combination with checkpoint inhibitors for NSCLC patients
- HotSpot Therapeutics raises $65M Series B
- Pandion Therapeutics appoints John Sundy as CMO
- Second Genome and Gilead Sciences announce strategic collaboration
- Pandion Therapeutics raises $80M Series B
- Design Therapeutics raises $45M Series A
- PsiOxus Therapeutics appoints Dr. Tom Lillie as CMO
- FDA approves TEPEZZA™ for the treatment of Thyroid Eye Disease